Table 5

Subgroup analyses of prescribed treatment groups in prevalent adult persons with alopecia areata in 2020 (n=4692)

TreatmentTopicalsSystemic biologicsSystemic non-biologicsSystemic GCS*
Age (years), p value<0.0010.158<0.001<0.001
 Up to 30, n(%)393 (7.9)2 (0.0)250 (5.0)44 (0.9)
 > 30–45, n(%)377 (7.6)1 (0.0)285 (5.7)64 (1.3)
 > 45–65, n(%)590 (11.9)5 (0.1)576 (11.6)207 (4.2)
 > 65, n(%)499 (10.0)0 (0.0)611 (12.3)215 (4.3)
Gender, p value<0.0010.471<0.001<0.001
 Male, n(%)559 (11.2)4 (0.1)370 (7.4)82 (1.6)
 Female, n(%)1300 (26.2)4 (0.1)1352 (27.2)448 (9.0)
Insurance district types, p value0.0020.2720.7230.588
 Urban, n(%)1315 (26.5)4 (0.1)1176 (23.7)365 (7.3)
 Rural, n(%)543 (10.9)4 (0.1)543 (10.9)163 (3.3)
Specialist, p value<0.001<0.001<0.001<0.001
 None of both, n(%)131 (7.0)2 (25.0)523 (30.4)187 (35.3)
 General practitioner, n(%)367 (19.7)0 (0.0)1038 (60.3)255 (48.1)
 Dermatologist, n(%)1184 (63.7)6 (75.0)116 (6.7)80 (15.1)
 Both n(%)177 (9.5)0 (0.0)45 (2.6)8 (1.5)
  • Bold values display significant differences.

  • *Subtype of non-biologics.

  • GCS, glucocorticosteroid.